Is it safe to proceed with kidney donation from a donor with active genital HSV‑1 infection, and what antiviral treatment and prophylaxis are required for donor and recipient?

Kidney Donation from Donor with Genital HSV-1

Kidney donation can safely proceed from a donor with genital HSV-1, as HSV transmission from donor to recipient is extremely rare, and the recipient should receive standard antiviral prophylaxis that would be given regardless of donor HSV status. 1

Safety of Proceeding with Donation

• Donor-derived HSV transmission is exceptionally uncommon in solid organ transplantation, making genital HSV-1 in the donor not a contraindication to kidney donation. 1
• The vast majority of HSV infections in transplant recipients result from reactivation of latent virus in seropositive recipients rather than donor transmission. 1
• Most transplant recipients are already seropositive for HSV-1 or HSV-2 prior to transplantation, making donor serostatus less clinically relevant. 1

Donor Management

• If the donor has active genital HSV-1 lesions at the time of planned donation, treat with oral acyclovir, valacyclovir, or famciclovir until all lesions have completely resolved before proceeding with organ procurement. 2
• Active lesions should be fully healed prior to donation to minimize any theoretical transmission risk, though this is primarily a precautionary measure rather than evidence-based requirement. 2
• Donors with a history of genital HSV-1 but no active lesions require no specific antiviral treatment prior to donation. 1

Recipient Prophylaxis Strategy

• All HSV-seropositive kidney transplant recipients should receive antiviral prophylaxis with acyclovir, valacyclovir, or famciclovir, regardless of donor HSV status. 1
• Recipients receiving ganciclovir or valganciclovir for CMV prophylaxis do not require additional HSV-specific prophylaxis, as these agents provide adequate HSV coverage. 1, 3
• For recipients not receiving CMV prophylaxis, HSV prophylaxis should be administered using acyclovir, valacyclovir, or famciclovir. 3
• Antiviral prophylaxis significantly reduces symptomatic HSV infections, with incidence dropping from 9.8% to 3% at one year post-transplant. 4

Duration of Prophylaxis

• Continue HSV prophylaxis for at least 3-6 months post-transplant, which corresponds to the period of highest immunosuppression and greatest HSV reactivation risk. 4
• Recipients experiencing frequent HSV recurrences after prophylaxis discontinuation should receive long-term suppressive antiviral therapy. 2

Treatment of Breakthrough Infections

• If the recipient develops superficial HSV lesions despite prophylaxis, treat with oral acyclovir, valacyclovir, or famciclovir until all lesions have completely resolved. 2
• For systemic HSV infection with visceral involvement, switch to intravenous acyclovir at doses up to 10 mg/kg every 8 hours and reduce immunosuppressive medications. 2, 1
• Continue IV acyclovir until clinical response is achieved, then transition to oral therapy to complete 14-21 days total treatment duration. 2

Critical Considerations

• Transplant recipients shed HSV more frequently, have more severe clinical manifestations, and respond more slowly to therapy compared to immunocompetent individuals, making prophylaxis essential. 1
• Female recipients have 1.7-fold higher risk of HSV infection post-transplant, warranting particularly vigilant prophylaxis adherence. 4
• HSV-seropositive recipients have 5-fold higher risk of symptomatic HSV disease, emphasizing the importance of pretransplant serologic screening. 4
• Acyclovir-resistant HSV is less common in solid organ transplant recipients than in hematopoietic stem cell transplant patients but should be considered if lesions fail to respond to standard therapy within 7-10 days. 1

Common Pitfalls to Avoid

• Do not defer kidney donation solely based on donor HSV-1 seropositivity or remote history of genital HSV-1, as this would unnecessarily exclude a large proportion of potential donors. 1
• Do not withhold antiviral prophylaxis from recipients based on donor HSV-negative status, as most HSV disease results from recipient reactivation rather than donor transmission. 1
• Do not use inadequate doses or short treatment courses designed for immunocompetent patients when treating active HSV infections in transplant recipients. 2